Alzheimer's disease (AD) is a neurodegenerative disease distinguished by progressive cognitive deterioration along with declining activities of daily living and behavioral changes. It is the commonest type of pre-senile and senile dementia. Many new therapeutic strategies have been developed in the last few years. We aimed at reviewing the evidence supporting these new therapeutic targets, including anti-amyloid and anti-Tau strategies. This review is focused on important future direction in investigation of potential therapeutic targets for AD drug discovery. Medical advances have improved treatment of many diseases but still there is a need to establish new tools for early diagnosis of AD. A thorough comprehensive understanding of the unexplored mechanism can ameliorate the diagnostic and therapeutic management of AD. There have been several disease-modifying therapeutic strategies for AD in the last few years and are presently at various phases of investigation. Few of them have shown promising results, but their safety and efficacy need to be further explored.
. Various biomarkers used in diagnosis of AD.
amyloid within significant specificity and reactivity [25] . However, neuropsychological analysis is considered to be the "gold standard" for pre-mortem detection of AD [26] , but the screening is tedious, and may demand manifold assessment.
Most of the AD drug development relevant biomarkers presently used are brain imaging, plasma and cerebrospinal fluid (CSF) measures; microarray and spectroscopic examination of multiple genes, proteins, lipids, metabolites. Florbetapir-PET (an imaging agent which has high binding specificity for β amyloid) images demonstrates that amyloid-β load associates with the cognitive function [27] . Another biomarker Aβ amyloid can also be analyzed using commercially available imaging agent (AV-45), for further research to understand AD; but still there is no imaging agent commercially available for tau. However, Victor Villemagne's research group is engaged in developing a tau imaging agent 18F-THK523 in patients [27] with Alzheimer and Jeff Kuret is also working on biomarkers for tau imaging for early analysis, differential analysis, and monitoring response to various treatments but selectivity and the binding potential are the key challenges in the development of tau imaging agents. In the frontotemporal dementia, enhanced sensitivity of a TDP-43 was observed during Cerebro Spinal Fluid (CSF) measurement [27] . Neuroimaging and CSF measures of β-amyloid and neuronal injury demonstrates the importance of the heterogeneity of the definition of neuronal injury, and has significant consequences for clinical trials exploiting biomarkers as substitute endpoint measures [28] .
Other major biomarkers developed so far include blood lipids [29] , saliva and metabolomics [30] , amyloid blood biomarker [31] [32] [33] [34] , retinal ganglion cell-inner plexiform layer (GCIPL) and nerve fiber layer (NFL) [35] . Plasma biomarkers have also been found to be very helpful in the detection of AD [35] . These biomarkers are economic and scalability bonus over existing techniques, facilitating broader clinical approach and productive population screening. Several proteins have been reported to play a significant role in the early detection of AD. A18kDatranslocator protein (TSPO) is known to have a promi-S. E. Tanwir, A. Kumar DOI: 10.4236/ojmc.2019. 91001 5 Open Journal of Medicinal Chemistry nent role in neuroinflammation in dementia pathogenesis and can aid in monitoring disease succession [36] . Another major protein Splicing factor prolineand glutamine-rich (SFPQ) which aids in transcription, pre-mRNA splicing, and DNA damage repair, was found to be dysregulated and dislocated in the development of AD and FTD [37] . Modifications in extracellular matrix proteins ameliorate hippocampal IL6 level and iron in the initial phases of AD and show inflammation-mediated iron dyshomeostasis in the initial phases of neurodegeneration. Besides, the level of iron in the hippocampus was calculated by preliminary coupled plasma-mass spectrometry as IL6 is cited in many studies to take part in iron homeostasis and inflammation and known to be elevated in 5XFAD mice hippocampus [38] . Further, Flavonoids-breviscapine biomarkers were investigated and were found to enhance the learning and memory deficits of AD mice chiefly by regulating phospholipids metabolism, promoting level of serotonin and reducing cholesterols content in vivo [39] . Noncoding MicroRNA (miR)-34a acts as a promising biomarker for early detection and intervention which contribute to the pathological development of AD [40] [41].
Multi-Target-Directed Ligand (MTDL) Design Strategy
Multi-target-directed-ligands (MTDLs) are found to be an innovative form of polypharmacology, which are compounds that influence two or more biological targets and processes [42] . This strategy has evolved vigorously over the past few years, mainly in the context of multifactorial diseases such as AD [43] [53] . It also revealed hippocampal cell proliferation activity in living adult mice. The role of ASS234 was identified as multi-target directed compound for AD [54] . Presently, the most effective therapeutic strategy for drug designing for AD is aiming the cholinergic system. It has been proposed that the decline of acetylcholine (ACh) level causes the cognitive and memory deficits [55] were assessed for multi-target activities associated with AD by Dias et al. [72] .
Among them, one compounds showed excellent AChEI activity, also had an- regulating inflammation response, encouraging microglia-mediated Aβendocytosis, and decrease cytokine secretion [82] . It was noticed that thiazolidinediones stimulated PPARγ to inhibit β-secretase and promoted ubiquitination to deteriorate amyloid load [83] . PPARγ agonists like thiazolidinediones derivatives rosiglitazone and pioglitazone lessen the peripheral insulin resistance [84] , which provoked AD neuropathology, and this decline of insulin sensitivity aids in Aβproteolysis. The study of rosiglitazone has been enhanced to a large phase; still, it has been terminated due to cardiac risk concerns [85] . These findings fortified the flavonoid baicalein effect as potent bioactive therapeutics that avoids memory deficit in AD patients [101] . This compound was also found to enhance scopolamine induced memory deficit in mice. An interesting fact about folic acid is that it prohibited the Aβ deposition due to folate deficiency in APP/PS1 mice. Folic acid decreased the accumulation of Aβ42 in APP/PS1 mice brain by reducing the mRNA and protein expressions of β-secretase BACE1 and γ-secretase complex catalytic component-presenilin 1 (PS1)-in APP/PS1 mice brain [102] . A compoundα7 nicotinic acetylcholine receptor (α7-nAChR) was raveled the association between α7-nAChR presence in the specific cholinergic region and cognitive decline in the AD patients [104] . Relation among Aβ burden and α7-nAChR decrease in the basal forebrain cholinergic system was underlined in accordance to AD cognitive decline. Furthermore, a series of 15 drug-like derivatives of 2-(benzylamino-2-hydroxyalkyl) isoindoline-1,3-diones were identified with β-secretase inhibitory activities [105] . Another compound, losteric M1 muscarinic and σ1 receptor agonist [124] . In female transgenic AD mice AF710B reduced cognitive impairments, also reduced BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. Clemens et al. validated the co-relation between inflammation, retinoic acid (RA) signaling, and Apolipoprotein E (ApoE) homeostasis in origin and development of AD [125] . Microglia is an important source of ApoE, and is known to be pathologically stimulated in AD. RA signaling is known to be inhibited by these microglia and proinflammatory stimulation reduces synthesis of ApoE, due to an effect blocked by RA. Sans et al. demonstrated the cellular model for evaluating apoE proteolysis, which showed that serine peptidase A1 (HtrA1) controlled apoE 25-kDa fragment production under physiological conditions, and depicts a novel neurotrophic effect for the apoE fragment [126] . Studies on CSF have shown that levels of CSF of amyloid-beta 1-42 (Aβ42) are decreased and tau levels ameliorated earlier to the commencement of cognitive decline related to AD. Leon et al. noticed that the prognosis of cognitive decline was enhanced by taking into account both high and low levels of Aβ42 [127] . Their data proposed a preliminary preclinical Selegiline, an irreversible and selective MAO-B inhibitor, has been described as a potent anti-AD agent because of its neuroprotective attribute in cellular and animal models of AD [138] . The elevated levels and dysregulation of biometal ions such as Cu 2+ , Zn 2+ and Fe 2+ were found to be closely involved in AD pathogenesis [139] and was reported to promote Aβ aggregation, resulting in the production of toxic Aβ oligomers [140] . Mitochondria association has been revealed in the disease pathogenesis of AD [150] . The member of quinone family is key mitochondrial targets used as the curative against ROS-mediated impairment. To avoid oxidative injury in AD, Mitoquinone mesylate or MitoQ, a ubiquinone derivative has been applied [151] . Zhang et al. discovered novel Phosphodiesterase-9 (PDE9) inhibitors [152] . This PDE9is a promising target for AD treatment. AD is marked by continuous cognitive decline, progressively associated with neuronal dysfunction caused by amyloid-β oligomers (AβOs). Diniz et al. reported that AβOs interact with astrocytes, triggers astrocyte activation and causes abnormal production of reactive oxygen species (ROS), which is accompanied by damage of astrocyte neuroprotective potential in vitro [153] . They demonstrated that astrocyte stops the synapse damage induced by AβOs, through formation of transforming growth factor-β1 (TGF-β1). AβOs also causes morphological and functional modifications in astrocytes, and weaken their neuroprotective potential. These findings outline a new strategy unrevealed the toxicity of AβOs and specify a novel therapeutic target for AD, primarily focused on TGF-β1 and astrocytes.
Yu et al. earlier reported that the inhibition of histone deacetylase 3 (HDAC3)
enhances spatial memory deficits and reduces the Aβ accumulation in the 9-month-old APP/PS1 mice brain [154] . Recently, they opened new frontiers for AD drug development by proposing HDAC3 to be a promising target because of their effect of reducing spatial memory deficits and preventing oxidative stress in APP/PS1 mice. HDAC3 is mainly present in the neurons; its inhibition notably attenuates production of ROS and enhanced primary cortical neuron viability.
Researchers determined a molecular association between aging and dementia via the identification of J147 a molecular target for the AD drug [155] . Mito- 
Targets and Small Molecules against Tauopathies
Tau accumulation association with neurodegeneration in AD and associated of Meynert (nbM) in AD [162] . They concluded that toxic tau oligomers multiply in selectively susceptible nbM neurons through the progression of AD.
Yang et al. designed the reagent for assessing plasma phosphorylated tau protein (p-tau181) with immunomagnetic reduction (IMR) and classified its analytic performances [163] . Their findings revealed that the level of plasma p-tau181 is associated more to AD severity than plasma T-tau.
Other Strategies
The anti-AD activities of different parts of Nelumbo nucifera (leaves, de-embryo seeds, embryos, rhizomes, and stamens) were explored to assess the selectivity and resourceful usage of its specific components [164] . ticity, whose damage leads to cognitive deficits in AD [175] . It was seen that proinflammatory peripheral blood mononuclear cell (PBMC)-derived cytokines level was ameliorated in AD patients as compared with healthy controls and donepezil treatment minimized proinflammatory cytokines [176] . Atorvastatin treatment notably enhanced cognitive deficits of rats, diminished microglia and activation of astrocyte, prevented apoptosis, and down-regulated the expression of TLR4, TRAF6, and NF-κB, at the mRNA and protein levels as well [177] .
TLR4 signaling pathway is therefore vigorously involved in Aβ-induced neuroinflammation and treatment with atorvastatin can exert therapeutic effects for AD. A nonselective β-adrenergic receptor blocker, Carvedilol, applied in the treatment for heart failure and hypertension, and has exhibited neuroprotective property due to its antioxidant attribute. [180] .
The role of erythropoietin-producing hepatocellular A4 (EphA4) in mediating hippocampal synaptic dysfunctions in AD was explored and it was seen that synaptic impairment is altered by the blockade of the ligand-binding domain of EphA4 in AD mouse models [181] . Their studies disclosed an anonymous role of EphA4 in facilitating AD-associated synaptic dysfunctions, indicating it to be a novel therapeutic target for treatment of AD. . Previously designed multitarget compounds include, dual binding AChE and BACE1 inhibitors [184] , AChE inhibitors and antioxidants [185] . Presently, multiple-pharmacology natural products can be employed in the drugs designing of AD treatment [186] , Herbal formulae like Kai-Xin-San (consisting of Ginseng Radix, Poria, Polygalae Radix, and Acori Tatarinowii Rhizoma) also found to be effective in the treatment of AD [187] [188]. Novel strategies, such as quantitative systems pharmacology [189] , chemogenomics knowledgebase [190] , metabolomics [191] [192] [193] [194] [195] [196] and chinmedomics [197] [198] [199] [200] [201] [202] can be further explored for the finding of new generation drugs for AD. Several reviews on different strategies employed for potential target have AD, the commonest dementia, is a rising worldwide health concern in today's world with immense implications for patients and societies as well. In this review, we have demarcated the current knowledge of the epidemiology, genetics, pathology and pathogenesis of AD, which is a prerequisite for the successful development of an effective therapy for the treatment of AD. Because the deposition of β-amyloid protein is a consistent pathological hallmark of brains affected by AD, the inhibition of Amyloid-β generation, prevention of Amyloid-β fibril formation, destabilization of pre-formed Amyloid-β would be an attractive the-Open Journal of Medicinal Chemistry rapeutic strategy for the treatment of AD. Finally, the review discusses the various strategies which can be applied for an effective treatment for AD. Given the diverse strategies employed to develop potent therapeutic approach, there is hope that a viable drug targeting key components will be developed in our fight against AD in the not too distant future.
Conclusions

